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According to the cancer immunoedit-
ing hypothesis, tumor cells—at least ini-
tially—are immunogenic and the adaptive 
immune system is involved in their active 
elimination.1 Among the immune cells that 
participate in this process, CD4+ helper T 
cells seem to play a major role in the gener-
ation and maintenance of effective antitu-
mor immunity.2 Thus, in humans, a high 
density of tumor-infiltrating Th1 cells has 
been shown to constitute a good prognos-
tic marker in several cancers.3 Pioneering 
work from Laurence Zitvogel and Guido 
Kroemer highlighted the capacity of some 
chemotherapy drugs to modulate antitu-
mor immunity.4 Understanding how the 
efficiency of chemotherapy is influenced 
by its effects on the immune system is 
one of the most challenging questions 
for tumor immunology. However, the 
impact of pre-existing tumor-specific Th1 
responses on the therapeutic potential of 
anticancer drugs has been poorly studied, 
mostly due to technical reasons.
In a recent study, we used newly identi-
fied pan-HLA-DR-derived epitopes from 
the human telomerase reverse transcrip-
tase (TERT), which we called univer-
sal cancer peptides (UCP), to monitor 
tumor-specific CD4+ Th1 cell responses. 
These UCPs could be recognized by 
CD4+ T cells isolated from different 
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types of cancer.5 The naturally occurring 
UCP-specific CD4+ T-cell response was 
studied in non-small cell lung carcinoma 
(NSCLC) patients using an interferon γ 
(IFNγ)-specific ELISPOT assay.
Among 84 metastatic NSCLC patients 
prospectively monitored prior to first 
line platinum-based chemotherapy, we 
detected spontaneous UCP-specific CD4+ 
Th1 responses in 38% of patients, while no 
response was found in healthy volunteers 
(n = 22). We then investigated the impact 
of the presence of UCP-specific CD4+ Th1 
cells on the clinical outcome, in particular 
the response to chemotherapy. We dem-
onstrated that the presence of anti-UCP 
immunity prior to treatment significantly 
increases the survival of chemotherapy-
responding patients, as compared with 
patients that do not manifest UCP-specific 
T-cell immunity (median overall survival: 
13.25 vs. 10 mo, p = 0.034).5 On other 
hand, patients with progressive disease 
after first line chemotherapy do not ben-
efit from UCP-specific immune responses. 
Of note, antiviral T-cell responses mea-
sured at the same time in the two groups of 
patients were similar and had no effect on 
survival, regardless of the response to che-
motherapy. In our knowledge, these results 
demonstrate for the first time a synergistic 
effect between pre-existing tumor-specific 
Th1 CD4+ T cell responses and chemo-
therapy in cancer patients.
There are several distinct mechanisms 
through which some chemotherapeu-
tic agents can modify the interactions 
between tumor cells and the host immune 
system.6 Through their action on cancer 
cells, chemotherapeutics can restore or 
enhance the expression of tumor antigens, 
making them more easily recognizable by 
the immune system. Anthracyclines and 
oxaliplatin have been shown to induce 
immunogenic cell death, resulting in the 
priming of antitumor immune responses.6 
In line with these observations, our data 
suggest that the tumor cell lysis induced by 
platinum-based chemotherapy promotes 
the release of TERT, which is taken up by 
antigen presenting cells that subsequently 
amplify pre-existing tumor-specific T 
cells. By contrast, when chemotherapy 
was ineffective, tumor cell lysis and the 
consequent release of TERT were insuf-
ficient for the amplification of antitumor 
immune cells (Fig. 1). This would explain 
why pre-existing UCP-specific immune 
responses did not influence overall survival 
in patients with chemotherapy-refractory 
progressive disease. UCP-specific CD4+ 
Th1 responses after first line chemother-
apy will be further monitored in NSCLC 
patients to confirm their persistence or 
Insights into antitumor t-cell responses may help the development of more eicient treatments for lung cancer. the 
interplay between pre-existing antitumor CD4+ t-cell responses and platinum-based chemotherapy is crucial to improve 
patient survival. Accumulating evidence conirms that selecting cancer patients in whom chemotherapy can activate an 
anticancer immune response would largely improve the success of novel therapeutic approaches.
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with the blockade of the PD1 pathway.10 
The use of antibodies that alleviate the 
inhibition of antitumor T-cell responses 
clearly require the presence of spontaneous 
antitumor immunity prior to treatment. 
Thus, monitoring NSCLC patients for 
the presence of naturally occurring antitu-
mor T-cell responses will allow for a better 
selection of patients for anti-PD1 therapy.
Collectively, our results provide a new 
tool for comprehensive monitoring of anti-
tumor CD4+ Th1 responses and support 
the concept of the immunomodulation of 
chemotherapy efficacy in cancer patients. 
Our findings also point to the therapeutic 
relevance of TERT as a target for immu-
notherapy. Thus, UCPs may be used to 
provide compensatory measures to restore 
or improve anticancer immune responses.
amplification. In line with our results, 
Weide et al. have recently reported that 
the presence of circulating Th1 cells 
responding to Melan-A or NY-ESO-1 has 
a strong independent prognostic impact 
on survival among chemotherapy-treated 
advanced melanoma patients.7 The impor-
tance of the interplay between antitumor T 
cells and conventional anticancer therapy 
is also supported by the improvement of 
tumor-specific immune responses observed 
in patients successfully treated by targeted 
agents such as imatinib mesylate or vemu-
rafenib (which inhibits c-KIT and BRAF, 
respectively).8,9
In addition, the implication of antitu-
mor T-cell responses on the clinical out-
come of NSCLC patients is supported by 
the impressive results recently obtained 
Figure 1. role of pre-existing antitumor CD4+ t-cell responses in the chemotherapy-induced immune regression of cancer. (A) efective chemothera-
py induces immunological tumor cell death and tumor antigen release. (B) tumor antigens are uptaked and processed by dendritic cells. (C) Activation 
of pre-existing tumor-speciic CD4 th1 cells promote an antitumor immunity that acts in synergy with chemotherapy efect.
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